| Measure | Agreement | Staff Education | EHR Reminders | Standing Orders | EHR Patient Education |
|---|---|---|---|---|---|
| Clinical process/effectiveness | |||||
| Antidepressant medication management | 90.9 (18.3) | 63.1 (23.8) | 50.8 (26.8) | N/A | 46.1 (23.5) |
| Asthma: use of appropriate medications | 97.0 (8.9) | 59.0 (22.6) | 53.1 (26.2) | N/A | 50.0 (23.8) |
| Blood pressure control | 96.5 (13.8) | 79.0 (20.3) | 74.6 (22.6) | N/A | 59.5 (23.4) |
| Cancer screening | |||||
| Breast | 97.2 (10.1) | 89.2*† (15.6) | 88.0*† (14.8) | 69.7* (36.9) | 61.0 (24.3) |
| Cervical | 98.0 (7.8) | 83.4* (19.2) | 83.6*† (19.4) | 39.7* (38.6) | 56.4† (25.7) |
| Colorectal | 99.8*† (1.1) | 85.9* (17.1) | 88.2*† (14.5) | 51.0* (40.6) | 60.2 (24.5) |
| Diabetes | |||||
| Poor control of hemoglobin A1C | 90.4 (16.2) | 78.2 (22.8) | 74.2 (25.9) | 63.7 (40.5) | 64.2*† (22.3) |
| LDL-C management | 91.6 (16.6) | 63.4 (24.2) | 68.0 (23.6) | 55.5 (41.1) | 64.2 (22.3) |
| Urine protein screening | 92.8 (20.2) | 74.9*† (22.0) | 80.2*† (23.2) | 64.6* (39.8) | 64.2* (22.3) |
| Heart failure | |||||
| ACE inhibitor or ARB therapy | 96.0 (14.5) | 54.7 (22.1) | 59.0*† (27.0) | N/A | 48.0 (24.8) |
| β-Blocker therapy | 96.5 (13.9) | 54.7 (22.1) | 56.2*† (27.2) | N/A | 48.0† (24.8) |
| Ischemic vascular disease | |||||
| Use of aspirin or another antithrombotic | 98.2 (7.5) | 64.4*† (23.9) | 75.8*† (23.8) | N/A | 54.4 (23.3) |
| LDL control | 94.0 (11.7) | 62.4 (24.6) | 64.0 (23.2) | 48.3 (41.2) | 54.5 (23.3) |
| Efficient resource use | |||||
| Appropriate treatment for children with upper respiratory infection | 89.8 (21.6) | 63.2* (27.1) | 36.5* (27.9) | N/A | 38.6* (26.5) |
| Patient safety | |||||
| Use of high-risk medications in the elderly | 91.7*† (18.9) | 56.8 (22.0) | 69.2 (20.8) | N/A | 43.5 (24.9) |
| Warfarin time in therapeutic range | 97.3 (13.7) | 76.8* (23.0) | 43.2 (29.2) | N/A | 49.3 (27.5) |
| Population/public health | |||||
| Chlamydia screening for women | 89.3* (25.1) | 65.7* (24.6) | 64.0*† (29.8) | 30.7* (35.7) | 45.4 (26.8) |
| Depression screening | 88.5 (23.2) | 69.1*† (26.6) | 67.7*† (29.5) | 41.2* (42.2) | 50.2* (29.7) |
| Influenza immunization | 97.9 (7.1) | 90.6* (14.5) | 88.2*† (14.7) | 82.0 (29.2) | 62.7 (25.1) |
| Pneumococcal immunization for older adults | 100.0 (0.0) | 88.0* (17.2) | 87.0*† (16.0) | 72.0* (35.0) | 62.3 (24.5) |
| Tobacco use screening and cessation intervention | 98.3 (8.5) | 86.2 (16.7) | 83.5 (17.7) | N/A | 62.6 (25.4) |
↵* Significantly (P < .05) correlated with corresponding quality measure in bivariate (unadjusted) analysis.
↵† Significantly (P < .05) correlated with corresponding quality measure in multivariate (adjusted) analysis.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; EHR, electronic health record; LDL-C, low-density lipoprotein cholesterol; N/A, not applicable; SD, standard deviation.